0.05Open0.05Pre Close0 Volume137 Open Interest65.00Strike Price0.00Turnover166.52%IV40.71%PremiumMay 9, 2025Expiry Date0.00Intrinsic Value100Multiplier3DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.0196Delta0.0065Gamma924.60Leverage Ratio-0.0380Theta0.0001Rho18.10Eff Leverage0.0021Vega
SpringWorks Therapeutics Stock Discussion
Acquisition brings two FDA-approved rare tumor therapies to Merck KGaA's portfolio, creating leadership position in high-unmet-need markets.
This acquisition strategically enhances Merck KGaA's position in specialized rare tumor markets by adding two recently FDA-approved therapies with distinctive market positions. SpringWorks contributes OGSIVEO® (nirogacestat), a first-in-class therapy established as the systemic standard-of...
Merck KGaA's $3.9B acquisition of SpringWorks offers 26% premium to shareholders while strategically expanding Merck's rare tumor portfolio.
The $47 per share all-cash acquisition of SpringWorks by Merck KGaA represents a 26% premium to SpringWorks' unaffected 20-day volume-weighted average price before market speculation. This translates to an equity value of approximately $3.9 billion and enterprise value of $3.4 billion (€3.0 billion), pr...
Merck KGaA's $3.9B SpringWorks Acquisition Brings Revolutionary Rare Disease Treatments Under Its Wing
EU Regulators Set to Rule on SpringWorks' Breakthrough Desmoid Tumor Treatment in Q2 2025
Germany's Merck says in late-stage discussions to buy SpringWorks for $3.5 billion - reuters.com/bus...
Exclusive: US pharma tariffs would raise US drug costs by $51 billion annually, report finds - reuters.com/bus...
It might cost cheaper to produce medicine 💊 oversea
WSJ· 5 mins ago
WSJ· 5 mins ago
No comment yet